Literature DB >> 19254395

Pheochromocytoma: a long-term follow-up of 24 patients undergoing laparoscopic adrenalectomy.

Lísias N Castilho1, Fabiano A Simoes, Andre M Santos, Tiago M Rodrigues, Carlos A dos Santos Junior.   

Abstract

PURPOSE: Pheochromocytomas are tumors derived from chromaffin cells that often secrete catecholamines and cause hypertension. The clinical diagnosis of pheochromocytoma depends on the presence of excessive production of catecholamines. Conventional imaging modalities that have been used in the preoperative evaluation include CT, MRI, and 131I-MIBG scintigraphy. Surgical resection is the definitive treatment for patients with pheochromocytoma. The goal of this study was to evaluate the long-term follow-up of 24 patients undergoing laparoscopic adrenalectomy for pheochromocytoma.
MATERIALS AND METHODS: From January 1995 to September 2006, 24 patients underwent laparoscopic adrenalectomy for adrenal pheochromocytoma. Twenty (83.3%) patients had arterial hypertension. The inclusion criteria of patients in this retrospective study were laparoscopic approach, unilateral or bilateral adrenal tumor, pathological diagnosis of pheochromocytoma and a minimum follow-up of 18 months.
RESULTS: Intra-operative complications occurred in 4 (16.7%) patients. Two (8.3%) patients had postoperative complications. Two patients (8.3%) had blood transfusion. The mean postoperative hospital stay was 3.8 days (range 1 to 11). Eighteen (90%) of the twenty patients who had symptomatic hypertension, returned to normal blood pressure immediately after surgery, during the hospital stay. In one patient, the high blood pressure levels remained unchanged. Another patient persisted with mild hypertension, well controlled by a single antihypertensive drug.
CONCLUSIONS: Our results confirmed that laparoscopic adrenalectomy for pheochromocytoma is a safe and effective procedure, providing the benefits of a minimally invasive approach. In our study, the initial positive results obtained in the treatment of 24 patients were confirmed after a mean follow-up of 74 months.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254395     DOI: 10.1590/s1677-55382009000100005

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  6 in total

Review 1.  Has laparoscopy impacted the indications for adrenalectomy?

Authors:  David W Hall; Jay D Raman
Journal:  Curr Urol Rep       Date:  2010-03       Impact factor: 3.092

2.  Retroperitoneal laparoscopy rather than an open procedure for resection of pheochromocytomas could minimize intraoperative blood pressure fluctuations and transfusion events.

Authors:  Wang Yanbo; Ding Xiaobo; Hou Yuchuan; Wang Yan; Jiang Fengming; Zhang Haifeng; Wang Chunxi
Journal:  Int Urol Nephrol       Date:  2010-09-17       Impact factor: 2.370

3.  Elemental Composition of Pheochromocytoma Resolved on Solid/Adrenal Tissue and Whole Blood Level.

Authors:  Jovana Jagodić; Branislav Rovčanin; Ivan Paunović; Mladen Mihailović; Nebojša Zečević; Dragan Manojlović; Aleksandar Stojsavljević
Journal:  Biol Trace Elem Res       Date:  2021-10-06       Impact factor: 3.738

4.  The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study.

Authors:  Ryszard Pogorzelski; Sadegh Toutounchi; Ewa Krajewska; Patryk Fiszer; Marcin Łykowski; Łukasz Zapała; Małgorzata Szostek; Wawrzyniec Jakuczun; Janusz Pachucki; Maciej Skórski
Journal:  Cent European J Urol       Date:  2014-12-05

5.  Pheochromocytoma with Takotsubo Syndrome and acute heart failure: a case report.

Authors:  Lin Yang; Yiying Zhang; Yanqun Hu; Zhi Yang
Journal:  World J Surg Oncol       Date:  2022-08-05       Impact factor: 3.253

6.  Laparoscopic approach to pheochromocytoma in pregnancy: case report.

Authors:  Felipe de Almeida E Paula; Ravisio Israel Dos Santos; Odivaldo Antonio Ferruzzi; Rafael Osti Melo; Mariana Takaku
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.